BR112018005932A2 - inibidores de isoindolinona da interação de mdm2-p53 que têm atividade anticâncer - Google Patents

inibidores de isoindolinona da interação de mdm2-p53 que têm atividade anticâncer

Info

Publication number
BR112018005932A2
BR112018005932A2 BR112018005932A BR112018005932A BR112018005932A2 BR 112018005932 A2 BR112018005932 A2 BR 112018005932A2 BR 112018005932 A BR112018005932 A BR 112018005932A BR 112018005932 A BR112018005932 A BR 112018005932A BR 112018005932 A2 BR112018005932 A2 BR 112018005932A2
Authority
BR
Brazil
Prior art keywords
mdm2
interaction
anticancer activity
compounds
isoindolinone
Prior art date
Application number
BR112018005932A
Other languages
English (en)
Other versions
BR112018005932B1 (pt
Inventor
Lewis Arwel
David Cons Benjamin
Paul Whittaker Benjamin
Thomas Golding Bernard
Florence Cano Celine
Norbert Johnson Christopher
Robert Mitchell Dale
Charles Rees David
Wyn Watson David
Charles Miller Duncan
Tamanini Emiliano
Chessari Gianni
Robert Hardcastle Ian
Maria Buck Ildiko
Daniel Osborne James
David St Denis Jeffrey
Peach Joanne
Louise Hirst Kim
Edward Mäntylä Noble Martin
Sara Holvey Rhian
John Griffin Roger (Falecido)
Cully Sarah
Howard Steven
Original Assignee
Astex Therapeutics Ltd
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd, Cancer Research Tech Ltd filed Critical Astex Therapeutics Ltd
Publication of BR112018005932A2 publication Critical patent/BR112018005932A2/pt
Publication of BR112018005932B1 publication Critical patent/BR112018005932B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

a presente invenção refre-se a um composto da fórmula (i): (i) ou tautômero ou um solvato ou um sal farmaceuticamente aceitável do mesmo, em que os diversos substituintes são conforme definido nas reivindicações. fornece-se também composições farmacêuticas que contêm os compostos da fórmula (i), processos para fazer os compostos e os usos médicos dos compostos.
BR112018005932-3A 2015-09-29 2016-09-29 Compostos inibidores de isoindolinona, seus processos de preparação, usos, combinações e composições farmacêuticas BR112018005932B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1517217.4 2015-09-29
GBGB1517217.4A GB201517217D0 (en) 2015-09-29 2015-09-29 Pharmaceutical compounds
PCT/GB2016/053042 WO2017055860A1 (en) 2015-09-29 2016-09-29 Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity

Publications (2)

Publication Number Publication Date
BR112018005932A2 true BR112018005932A2 (pt) 2018-10-09
BR112018005932B1 BR112018005932B1 (pt) 2023-11-28

Family

ID=54544291

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018005932-3A BR112018005932B1 (pt) 2015-09-29 2016-09-29 Compostos inibidores de isoindolinona, seus processos de preparação, usos, combinações e composições farmacêuticas

Country Status (27)

Country Link
US (3) US10544132B2 (pt)
EP (2) EP3356350B1 (pt)
JP (2) JP7029387B2 (pt)
KR (1) KR20180081706A (pt)
CN (2) CN108290871B (pt)
AU (2) AU2016330030C1 (pt)
BR (1) BR112018005932B1 (pt)
CA (1) CA2999400A1 (pt)
DK (1) DK3356350T3 (pt)
ES (1) ES2934181T3 (pt)
FI (1) FI3356350T3 (pt)
GB (1) GB201517217D0 (pt)
HK (1) HK1250715A1 (pt)
HR (1) HRP20221487T1 (pt)
HU (1) HUE060638T2 (pt)
IL (1) IL258213B (pt)
LT (1) LT3356350T (pt)
MA (1) MA43032A (pt)
MX (1) MX2018004008A (pt)
PH (1) PH12018500610A1 (pt)
PL (1) PL3356350T3 (pt)
PT (1) PT3356350T (pt)
SA (1) SA518391218B1 (pt)
SG (1) SG10201912833XA (pt)
SI (1) SI3356350T1 (pt)
TW (1) TWI761315B (pt)
WO (1) WO2017055860A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
CA3037626A1 (en) * 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) * 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
CN107118183B (zh) * 2017-05-17 2021-02-02 成都化润药业有限公司 一种四氢-3-呋喃甲醇的合成方法
WO2019061324A1 (en) 2017-09-29 2019-04-04 Curis Inc. CRYSTALLINE FORMS OF IMMUNOMODULATORS
BR112020006669A2 (pt) * 2017-10-11 2020-09-24 Aurigene Discovery Technologies Limited formas cristalinas de 1,2,4-oxadiazol 3-substituído
KR20200084333A (ko) 2017-11-06 2020-07-10 오리진 디스커버리 테크놀로지스 리미티드 면역조절을 위한 병행 요법
MX2020009614A (es) * 2018-03-20 2020-10-07 Novartis Ag Combinaciones farmaceuticas.
CN110194760B (zh) * 2019-05-27 2021-08-17 浙江农林大学暨阳学院 制备3-亚苄基-2-（7’-喹啉）-2,3-二氢-异吲哚-1-酮类化合物的方法
CN118027041A (zh) * 2019-05-31 2024-05-14 西藏海思科制药有限公司 一种btk抑制剂环衍生物及其制备方法和药学上的应用
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
KR20230022402A (ko) * 2020-04-29 2023-02-15 릴레이 테라퓨틱스, 인크. PI3Kα 억제제 및 이의 사용 방법
CN116194088A (zh) 2020-08-27 2023-05-30 大冢制药株式会社 使用mdm2拮抗剂治疗癌症的生物标志物
CN112022812B (zh) * 2020-11-03 2021-01-29 上海亚盛医药科技有限公司 一种包含杂环类化合物的组合物、其制备方法和应用
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
WO2023098880A1 (zh) * 2021-12-02 2023-06-08 上海翰森生物医药科技有限公司 稠环类衍生物调节剂、其制备方法和应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH374071A (de) 1959-04-30 1963-12-31 Geigy Ag J R Verfahren zur Herstellung von neuen Isoindolinderivaten
US3466298A (en) 1967-03-14 1969-09-09 American Home Prod Process for the preparation of 2-(2-aminoethyl)isoindolines
US3763178A (en) 1968-09-05 1973-10-02 American Home Prod Imidazolinyl phenyl carbonyl acid addition salts and related compounds
GB1325066A (en) 1970-02-12 1973-08-01 American Home Prod Phthalimidine compounds
AR203991A1 (es) 1972-03-16 1975-11-12 Rhone Poulenc Sa Procedimiento para preparar derivados de(hidroxi-2-amino-3-propoxi)-3-isoindolinona-1
FR2217000B1 (pt) 1973-02-08 1976-04-09 Rhone Poulenc Ind
GB1601701A (en) 1977-07-22 1981-11-04 Delmar Chem Production of heterocyclic benzamide compounds
US4200759A (en) 1978-07-20 1980-04-29 Delmar Chemicals, Limited Preparation of imidazo[2,1-a]isoindole compounds
US4244966A (en) 1979-09-24 1981-01-13 American Home Products Corporation 1,3-Dihydro-3-(2-hydroxy-, 2-bromo- or 2-chloroethyl)-2H-isoindol-1-one derivatives
US4331600A (en) 1980-10-31 1982-05-25 Usv Pharmaceutical Corporation Intermediates for the synthesis of phthalimidines
US4312809A (en) 1980-10-31 1982-01-26 E. R. Squibb & Sons, Inc. Lactam derivatives of mercaptoacylamino acids
FR2533563A1 (fr) 1982-09-23 1984-03-30 Adir Nouveaux derives de la sulfonyluree, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
HU212435B (en) 1990-06-07 1996-06-28 Sandoz Ag Herbicidal compositions containing substituted phthalides and heterocyclic phthalides as active ingredient and process for preparation of their active ingredients.
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
TW448172B (en) 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
DE19807423A1 (de) 1998-02-21 1999-08-26 Hoechst Marion Roussel De Gmbh Subustituierte Isoindolone, ihre Herstellung und ihre Verwendung in Arzneimitteln
EP1557168B1 (en) 1999-07-26 2011-11-16 Msd K.K. Biarylurea Derivatives
WO2001032928A2 (en) 1999-11-05 2001-05-10 Phase-1 Molecular Toxicology Methods of determining individual hypersensitivity to an agent
DE10134482A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte Isoindole und ihre Verwendung
EP1458380B1 (en) 2001-12-18 2008-03-19 F.Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors
FR2840302B1 (fr) 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
BR0316645A (pt) 2002-11-26 2005-10-11 Maruishi Pharma Derivados de isoindol
JP2004217591A (ja) 2003-01-16 2004-08-05 Dai Ichi Seiyaku Co Ltd シス選択的フルオロシクロプロパン誘導体の製造方法
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
JP2005255660A (ja) 2004-03-10 2005-09-22 Katsuhiko Tomooka 多官能基を有するラクタム類とその製法
WO2005095341A1 (ja) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. 含窒素複素環化合物
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
EA019566B1 (ru) 2005-02-22 2014-04-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Низкомолекулярные ингибиторы mdm2
US7705021B2 (en) * 2005-05-02 2010-04-27 Fox Chase Cancer Center Isoindolone compounds, compositions containing the same, and methods of use thereof for the treatment of viral infections related to the etiology of cancer
EP1912940A1 (en) 2005-08-12 2008-04-23 AstraZeneca AB Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2008047831A1 (fr) 2006-10-17 2008-04-24 Kyowa Hakko Kirin Co., Ltd. Inhibiteurs de JAK
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
WO2008151184A1 (en) 2007-06-03 2008-12-11 Vanderbilt University Benzamide mglur5 positive allosteric modulators and methods of making and using same
US20090156735A1 (en) * 2007-12-14 2009-06-18 General Electric Company Composition, article, and associated method
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
DE102008031517A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
CN102159207B (zh) 2008-09-18 2015-02-04 霍夫曼-拉罗奇有限公司 取代的吡咯烷-2-甲酰胺类
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
FR2944282B1 (fr) 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
UA107814C2 (uk) 2009-11-12 2015-02-25 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Спірооксіндольні антагоністи мdм2
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
PL2684880T3 (pl) 2011-03-10 2018-07-31 Daiichi Sankyo Company, Limited Pochodna dispiropirolidyny
EP2721008B1 (en) 2011-06-20 2015-04-29 Novartis AG Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
EP2721007B1 (en) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl isoquinolinone compounds
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
KR101401705B1 (ko) 2012-01-31 2014-06-27 울산대학교 산학협력단 로듐 촉매를 이용한 이소인돌린 유도체의 합성방법
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013157022A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
JP6343285B2 (ja) 2012-10-30 2018-06-13 メイ ファーマ, インク.Mei Pharma, Inc. 併用療法
KR101879926B1 (ko) 2013-07-03 2018-08-16 에프. 호프만-라 로슈 아게 MDM2 길항제를 사용한 환자 암 치료를 개인화하기 위한 mRNA-기반 유전자 발현
EP3094746A1 (en) 2014-01-14 2016-11-23 Daiichi Sankyo Company, Limited Gene signatures associated with sensitivity to mdm2 inhibitors
JP6694827B2 (ja) 2014-04-17 2020-05-20 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン Ｍｄｍ２阻害剤及びそれを使用する治療方法
JP2017532959A (ja) 2014-10-09 2017-11-09 第一三共株式会社 Ｍｄｍ２阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム
EP3206697A2 (en) 2014-10-17 2017-08-23 Biomirna Holdings Ltd. Lung cancer diagnostics and therapeutics with mir-660
GB201517217D0 (en) * 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) * 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
AU2016341520C1 (en) 2015-10-21 2021-07-22 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
US11339448B2 (en) 2018-07-27 2022-05-24 Ottawa Hospital Research Institute Treatment of acute myeloid leukemia
CN111607647A (zh) 2019-02-24 2020-09-01 苏州亚盛药业有限公司 Mdm2抑制剂的治疗方法和生物标志物
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
CN116194088A (zh) 2020-08-27 2023-05-30 大冢制药株式会社 使用mdm2拮抗剂治疗癌症的生物标志物
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers

Also Published As

Publication number Publication date
US10981898B2 (en) 2021-04-20
AU2016330030C1 (en) 2022-03-10
WO2017055860A1 (en) 2017-04-06
IL258213A (en) 2018-05-31
CN115572252A (zh) 2023-01-06
HUE060638T2 (hu) 2023-04-28
PL3356350T3 (pl) 2023-01-23
TW201722914A (zh) 2017-07-01
PH12018500610A1 (en) 2018-09-24
JP7029387B2 (ja) 2022-03-03
HRP20221487T1 (hr) 2023-02-03
AU2016330030A1 (en) 2018-04-12
US20200247789A2 (en) 2020-08-06
JP2018534253A (ja) 2018-11-22
US20200079761A1 (en) 2020-03-12
AU2016330030B2 (en) 2021-02-18
AU2021202962A1 (en) 2021-06-03
FI3356350T3 (fi) 2023-01-13
EP3356350B1 (en) 2022-11-16
NZ740737A (en) 2021-10-29
PT3356350T (pt) 2022-12-27
HK1250715A1 (zh) 2019-01-11
SG10201912833XA (en) 2020-02-27
AU2021202962B2 (en) 2023-01-12
ES2934181T3 (es) 2023-02-17
TWI761315B (zh) 2022-04-21
US12071429B2 (en) 2024-08-27
SI3356350T1 (sl) 2023-03-31
CN108290871B (zh) 2022-08-23
JP2022070998A (ja) 2022-05-13
AU2021202962C1 (en) 2023-08-10
JP7566806B2 (ja) 2024-10-15
GB201517217D0 (en) 2015-11-11
CA2999400A1 (en) 2017-04-06
KR20180081706A (ko) 2018-07-17
BR112018005932B1 (pt) 2023-11-28
US10544132B2 (en) 2020-01-28
SA518391218B1 (ar) 2022-12-22
EP3356350A1 (en) 2018-08-08
LT3356350T (lt) 2023-01-10
IL258213B (en) 2021-10-31
US20190016708A1 (en) 2019-01-17
DK3356350T3 (da) 2022-12-19
MX2018004008A (es) 2018-11-09
MA43032A (fr) 2018-08-08
US20210276984A1 (en) 2021-09-09
CN108290871A (zh) 2018-07-17
EP4151633A1 (en) 2023-03-22

Similar Documents

Publication Publication Date Title
BR112018005932A2 (pt) inibidores de isoindolinona da interação de mdm2-p53 que têm atividade anticâncer
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112018003595A2 (pt) análogos de nucleosídeos substituídos no anel aromático 6-6 bicíclico para uso como inibidores de prmt5
EA033343B1 (ru) Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой
BR112018076169A2 (pt) derivados azabenzimidazol como inibidores de pi3k beta
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
PH12018500626A1 (en) Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018500576A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
MX2018011788A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
EA201692000A1 (ru) Макроциклические производные пиридина
NZ733313A (en) Indole derivatives as dengue viral replication inhibitors
CU20160020A7 (es) Derivados de imidazoquinolinas sustituidas inhibidores de mek para el tratamiento del cáncer
EA201692003A1 (ru) Макроциклические производные пиримидина
BR112019006414A2 (pt) análogos de carbanucleosídeos de sistema de anel monocíclico e bicíclico substituídos para uso como inibidores de prmt5
DOP2014000059A (es) Derivados de estra–1,3,5(10),16–tetraen–3–carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
TR201908265T4 (tr) Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri.
ECSP15000868A (es) Derivados de estra–1,3,5(10),16–tetraeno 3–sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112017010645A2 (pt) derivados da piridinocarboxamida, método de preparação dos mesmos e usos farmacêuticos dos mesmos
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112018007128A2 (pt) compostos para a inibição de câncer e epigênese
BR112018007068A2 (pt) derivados de quinoxalina e piridopirazina como inibidores de pi3kbeta

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/09/2016, OBSERVADAS AS CONDICOES LEGAIS